VERA (Vera Therapeutics, Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by VERA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Nancy Lee Boman | Chief Regulatory Officer | A | — | — |
| 2026-07-09 | Marshall Fordyce | PRESIDENT AND CEO | Sell | — | — |
| 2026-06-24 | Marshall Fordyce | PRESIDENT AND CEO | Sell | — | — |
| 2026-05-26 | Scott W Morrison | Director | A | — | — |
| 2026-05-26 | BETH C SEIDENBERG | Director | A | — | — |
| 2026-05-26 | PATRICK G ENRIGHT | Director | A | — | — |
| 2026-05-26 | James R Meyers | Director | A | — | — |
| 2026-05-26 | Christy J. Oliger | Director | A | — | — |
| 2026-05-26 | MICHAEL MORRISSEY | Director | A | — | — |
| 2026-05-26 | Kimball Hall | Director | A | — | — |
| 2026-05-26 | Andrew Cheng | Director | A | — | — |
| 2026-05-13 | Marshall Fordyce | PRESIDENT AND CEO | Sell | — | — |
| 2026-04-15 | Marshall Fordyce | PRESIDENT AND CEO | Sell | — | — |
| 2026-03-25 | Jane Wright-Mitchell | Chief Legal Officer | A | — | — |
| 2026-03-16 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | M | — | — |
| 2026-03-09 | Christopher Hite | Director | A | — | — |
| 2026-02-25 | DAVID LEE JOHNSON | Chief Operating Officer | Sell | — | — |
| 2026-02-25 | William D. Turner | Chief Regulatory Officer | Sell | — | — |
| 2026-02-25 | Robert Brenner | Chief Medical Officer | Sell | — | — |
| 2026-02-25 | Marshall Fordyce | PRESIDENT AND CEO | Sell | — | — |
| 2026-02-25 | Laurence Matthew Skelton | Chief Commercial Officer | Sell | — | — |
| 2026-02-25 | Sean Grant | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2026-02-25 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | Sell | — | — |
| 2026-02-06 | Sean Grant | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-02-06 | DAVID LEE JOHNSON | Chief Operating Officer | A | — | — |
| 2026-02-06 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | A | — | — |
| 2026-02-06 | Laurence Matthew Skelton | Chief Commercial Officer | A | — | — |
| 2026-02-06 | William D. Turner | Chief Regulatory Officer | A | — | — |
| 2026-02-06 | Marshall Fordyce | PRESIDENT AND CEO | A | — | — |
| 2026-02-06 | Robert Brenner | Chief Medical Officer | A | — | — |
| 2025-12-17 | William D. Turner | Chief Regulatory Officer | MIXED | — | — |
| 2025-12-15 | PATRICK G ENRIGHT | Director | Buy | — | — |
| 2025-12-10 | William D. Turner | Chief Regulatory Officer | MIXED | — | — |
| 2025-12-04 | William D. Turner | Chief Regulatory Officer | MIXED | — | — |
| 2025-11-26 | James R Meyers | Director | A | — | — |
| 2025-11-25 | Jason S Carter | Chief Legal Officer | Sell | — | — |
| 2025-11-13 | Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | MIXED | — | — |
| 2025-06-25 | PATRICK G ENRIGHT | Director | Buy | — | — |
| 2025-05-16 | Maha Katabi | Director | A | — | — |
| 2025-05-16 | MICHAEL MORRISSEY | Director | A | — | — |
| 2025-05-16 | Christy J. Oliger | Director | A | — | — |
| 2025-05-16 | BETH C SEIDENBERG | Director | A | — | — |
| 2025-05-16 | Kimball Hall | Director | A | — | — |
| 2025-05-16 | PATRICK G ENRIGHT | Director | A | — | — |
| 2025-05-16 | Andrew Cheng | Director | A | — | — |
| 2025-05-16 | Scott W Morrison | Director | A | — | — |
| 2025-02-27 | Marshall Fordyce | PRESIDENT AND CEO | Sell | — | — |
| 2025-02-20 | William D. Turner | Chief Development Officer | A | — | — |
| 2025-02-20 | Sean Grant | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-02-20 | DAVID LEE JOHNSON | Chief Operating Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 7,062,846 | — |
| — | 10%+ Owner | 4,400,000 | — |
| — | Director | 3,602,475 | — |
| — | 10%+ Owner | 3,429,927 | — |
| — | 10%+ Owner | 3,429,927 | — |
| — | 10%+ Owner | 3,096,594 | — |
| — | Director | 2,978,059 | — |
| — | 10%+ Owner | 2,966,875 | — |
| — | 10%+ Owner | 2,187,504 | — |
| — | PRESIDENT AND CEO | 277,143 | — |
| — | Director | 135,565 | — |
| — | CHIEF FINANCIAL OFFICER | 119,181 | — |
| — | SVP, FINANCE, CHIEF ACCT OFFCR | 75,754 | — |
| — | Chief Commercial Officer | 64,218 | — |
| — | Chief Medical Officer | 50,947 | — |
| — | Chief Legal Officer | 49,136 | — |
| — | Chief Operating Officer | 45,727 | — |
| — | Chief Regulatory Officer | 45,313 | — |
| — | Chief Legal Officer | 42,403 | — |
| — | Chief Development Officer | 26,962 | — |
| — | Director | 17,488 | — |
| — | Chief Medical Officer | 11,010 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VERA quote page; the site-wide leaderboard is on the insider transactions hub.